Trimipramine


Tricyclic antidepressant (sedating tertiary amine)

A sedating tertiary amine TCA with weak SERT and NET activity; the principal effect is dopaminergic and antihistaminergic.

Abstract

Trimipramine (3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine; CAS 739-71-9; molecular formula C20H26N2; molecular weight 294.43) is a 2-methylated dibenzazepine TCA approved by the FDA in 1979 under the trade name Surmontil. The methyl substitution at the propanamine’s beta carbon disrupts transporter binding: SERT Ki approximately 150 nM, NET Ki approximately 2400 nM, both several orders of magnitude weaker than amitriptyline or imipramine. The therapeutic effect is therefore primarily attributed to potent H1 (Ki approximately 0.27 nM, comparable to first-generation antihistamines), 5-HT2A, alpha-1, and D2 antagonism. The compound is among the most sedating TCAs in clinical use and is used preferentially in depression with severe insomnia. Plasma half-life is 16 to 40 hours; metabolism is via CYP2D6, CYP2C19, CYP3A4. Used as a reference compound for non-transporter TCA mechanism research; the H1 and dopaminergic profiles distinguish it from typical TCA pharmacology.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph